Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations

Vaccine

Volumn 31, Issue 42, 2013, Pages 4881-4887

  Hackel, M ^a   Lascols, C ^a   Bouchillon, S ^a   Hilton, B ^b   Morgenstern, D ^b   Purdy, J ^b  

^a Division of Microbiology   (United States)

^b PFIZER INC   (United States)

Author keywords

Antibiotic resistance; Invasive pneumococcal disease; Pneumococcal conjugate vaccine; Prevenar; Serotype; Streptococcus pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; DNA; ERYTHROMYCIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; TIGECYCLINE;

ADOLESCENT; ADULT; AFRICA; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CHILD; HUMAN; MAJOR CLINICAL STUDY; MIDDLE EAST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEROPREVALENCE; SEROTYPE; SOUTH AND CENTRAL AMERICA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANTIBIOTIC RESISTANCE; INVASIVE PNEUMOCOCCAL DISEASE; PNEUMOCOCCAL CONJUGATE VACCINE; PREVENAR; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PREVALENCE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; WORLD HEALTH; YOUNG ADULT;

EID: 84884209745     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.054     Document Type: Article

References (41)

1. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Seminars in Respiratory and Critical Care Medicine 2009, 30(2):189-209.
2. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgraduate Medicine 2010, 122(March (2)):130-141.
3. Gil-Prieto R., García-García L., Alvaro-Meca A., Méndez C., García A., de Miguel A.G. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine 2011, 29(November (3)):412-416. [Epub 2010].
4. Restrepo M.I., Heyder A., Choudhri S.H. Severe community-acquired pneumonia. Infectious Disease Clinics of North America 2009, 23(3):503-520.
5. Shibl A.M., Memish Z.A., Ibrahim E., Kanj S.S. Burden of adult community-acquired pneumonia in the Middle East/North Africa region. Review in Medical Microbiology 2010, 21(1):11-20.
6. Vila-Corcoles A., Ochoa-Gondar O., Rodriguez-Blanco T., Raga-Luria X., Gomez-Bertomeu F. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Resp Med 2009, 103(September (2)):309-316. [Epub 2008].
7. Song J., Thamlikitkul V., Hsueh P. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. International Journal of Antimicrobial Agents 2001, 38(June (2)):108-117. [Epub 2011].
8. Musher D.M. Infections caused by Streptococcus pneumoniae: clinical spectrum pathogenesis immunity treatment. Clinical Infectious Diseases 2009, 14:801-807.
9. Musher D.M. Streptococcus pneumoniae. Principles and practices of infectious disease 2010, Churchill Livingston Elsevier, Philadelphia, PA, US, [chapter 200]. 7th ed.
10. Epidemiology and prevention of vaccine-preventable diseases. The Pink Book: course textbook 2011, April, Chapter 16 Pneumococcal Disease (http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html). 12th ed.
11. Obrien K., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
12. Centers for Disease Control and Prevention. 2009. Active Bacterial Core Surveillance Report. Emerging Infections Program Network, Streptococcus pneumoniae 2008.
13. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases 2006, Public Health Foundation, Washington, DC. 9th ed. W. Atkinson, J. Hamborsky, S. Wolfe (Eds.).
14. Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clinical Infectious Diseases 2000, 30:100-121.
15. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. Journal of Clinical Microbiology 1995, 33:2759-2762.
16. Park I.H., Pritchard D.G., Cartee R., Brandao A., Brandileone M.C., Nahm M.H. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. Journal of Clinical Microbiology 2007, 45:1225-1233.
17. Jacobs M.R., Bajaksouzian S., Bonomo R.A., Good C.E., Windau A.R., Hujer A.M., et al. Occurrence, distribution, and origins of Streptococcus pneumoniae serotype 6 C, a recently recognized serotype. Journal of Clinical Microbiology 2009, 47:64-72.
18. Hausdorff W.P., Feikin D.R., Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infectious Diseases 2005, 5:83-93.
19. Domenech de Cellès M., Opatowski L., Salomon J., Varon E., Carbon C., Boëlle P.Y., Guillemot D. Intrinsic epidemicity of Streptococcus pneumoniae depends on strain serotype and antibiotic susceptibility pattern. Antimicrobial Agents and Chemotherapy 2011, 55:5255-5261.
20. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Journal of Infectious Diseases 2010, 201:32-41.
21. Weinberger D., Harboe Z.B., Sanders E.A., Ndiritu M., Klugman K.P., Rückinger S., et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis. 2010, 51(6):692-699.
22. Jones R.N., Jacobs M.R., Sader H.S. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. International Journal of Antimicrobial Agents 2010, 36(June (3)):197-204. [Epub 2010].
23. Cooke B., Smith A., Diggle M., Lamb K., Robertson C., Inverarity D., et al. Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007. Journal of Medical Microbiology 2010, 59(10):1212-1218.
24. Liñares J., Ardanuy C., Pallares R., Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clinical Microbiology and Infection 2010, 16:402-410.
25. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., Elvin L., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatric Infectious Disease Journal 2000, 19(3):187-195.
26. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. New England Journal of Medicine 2001, 344:403-409.
27. Kyaw M.H., Lynfield R., Schaffner W., Craig A.S., Hadler J., Reingold A. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. New England Journal of Medicine 2006, 354:1455-1463.
28. Lexau C.A., Lynfield, Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. Journal of the American Medical Association 2005, 294:2043-2051.
29. Jacobs M.R., Good C.E., Beall S.B., Bajaksouzian S., Windau A.R., Whitney C.G. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. Journal of Clinical Microbiology 2008, 46:982-990.
30. Hoban D.J., Bouchillon S.K., Johnson B.M., Johnson J.L., Dowzicky M.J., Tigecycline Evaluation, Surveillance Trial (TEST Program) Group In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagnostic Microbiology and Infectious Disease 2005, 52:215-227.
31. York M., Traylor M.M., Hardy J., Henry M. Clinical microbiology procedures handbook 2010, ASM Press, Washington, DC. 3rd ed.
32. Clinical Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards 2009, CLSI Document M07-A8, Wayne, PA. 8th ed.
33. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement 2011, CLSI Document M100-S21, Wayne, PA.
34. Pai R., Gertz R.E., Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. Journal of Clinical Microbiology 2006, 44:124-131.
35. Austrian R. The quellung reaction, a neglected microbiologic technique. Mount Sinai Journal of Medicine 1976, 43:699-709.
36. Dagan R., Melamed R., Muallem M., Piglansky L., Greenberg D., Abramson O., et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate vaccine. Journal of Infectious Diseases 1996, 174:1271-1277.
37. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine 2003, 348:1737.
38. Miller E.N., Andrews J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet 2011, 11:760-768.
39. Obaro S., Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. Journal of Medical Microbiology 2002, 51:98-104.
40. Farrell D.J., Klugman K.P., Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of the 7-valent pneumococcal vaccine in the United States. Pediatric Infectious Disease Journal 2007, 26:123-128.
41. Moore M.R., Gertz R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. Journal of Infectious Diseases 2008, 197:1016-1026.